Oncogenic Driver Mutations/Biomarkers in Screening Participants for Early Detection of Lung Cancer
Primary Objectives To identify and validate Oncogenic Driver Mutations/Biomarkers for the early detection of lung cancer in individuals at high-risk for lung cancer. These mutations/biomarkers of interest include those seen in EGFR, k-ras, HER-2, BRAF, PI3KCA, DDR2, PTEN, TP53, RB1, CREBBP, EP300, SLIT2, MLL, EPHA7, and EML4/ALK gene rearrangement.
Secondary Objectives To characterize the nodules and preneoplastic lesions in screening participants with presence/absence of Oncogenic Drivers Mutations/Biomarkers in an attempt to develop personalized approaches to management and follow-up. This will lead to individualizing therapy for these subjects at high- risk for development of lung cancer.